AR and posterior cortical atrophy: Treatment strategies for advanced PCa follow the goal to prolong survival through targeting key drivers of carcinogenesis, where the androgen receptor pathway plays a crucial role and androgen deprivation therapy (ADT) remains the backbone of therapy in metastatic hormone-sensitive prostate cancer (mHSPC) in combination with other novel agents [3].